OpenEvidence, an AI-driven medical search platform used by physicians across the U.S., has closed a Series D funding round that values the company at $12 billion. The round raised $250 million and was co-led by Thrive Capital and DST Global, bringing total funding over the past year to about $700 million.
OpenEvidence provides clinicians with real-time, citation-linked answers drawn exclusively from peer-reviewed medical journals and clinical guidelines. Founded by Daniel Nadler, the company focuses on helping doctors keep pace with rapidly changing medical evidence. “Doctors want to provide the best care to patients, but they simply do not have the time to review every new study and guideline,” Nadler said, adding that OpenEvidence safely gives them access to the knowledge they need to make better decisions.
The new funding will support research, development, and computing resources behind OpenEvidence’s multi-model AI architecture, which routes clinical questions to specialized systems trained on specific medical fields. The platform relies on formal partnerships with organizations such as the New England Journal of Medicine and the American Medical Association, a strategy that has helped build trust among physicians. According to the company, in 2025, more than 100 million Americans were treated by doctors using OpenEvidence. Kareem Zaki, Partner at Thrive Capital, stated, “OpenEvidence is effectively the default operating system of medical knowledge in the United States today.”
